Amgen 8-K
Debt financing
Senior unsecured note issuance adds debt across four maturities extending to 2056.
Filed 2026-02-19 16:27 ET
- 1.01 Entry into a Material Agreement
- 9.01 Financial Statements and Exhibits
Summary
Amgen issued $4B of senior unsecured notes across four maturities, generating approximately $3.96B in net proceeds. The filing does not state how proceeds will be used; the notes add debt with maturities from 2031 to 2056.
Key Figures
- Principal: $1B of 4.200% notes due 2/19/2031; $1.75B of 4.850% notes due 2/19/2036; $500M of 5.500% notes due 2/19/2046; and $750M of 5.650% notes due 2/19/2056.
- Net proceeds: approximately $3.96B after underwriting discounts and estimated offering expenses. Interest is payable semiannually beginning 8/19/2026.
- On a change-in-control triggering event, holders may require Amgen to repurchase notes for 101% of principal plus accrued and unpaid interest. The notes rank equally with Amgen’s senior unsecured debt and are effectively subordinated to subsidiary obligations and secured obligations to the extent of collateral.
The summary is written by an AI model reading the filing.
Model 005 · prompt 01d34d48e3